Researchers have discovered that a decades-old drug, DFMO (difluoromethylornithine), may offer hope for children suffering from Bachmann-Bupp syndrome (BABS), a rare and life-threatening genetic disorder. Originally developed to treat sleeping sickness, DFMO has shown promising results in easing severe symptoms of BABS by targeting the genetic malfunction responsible for the disorder. This new application is being explored through a collaborative effort between Corewell Health, Michigan State University, and Every Cure, a nonprofit focused on repurposing existing medications.

For families affected by BABS, which impacts only about 20 individuals worldwide, this development could mean a significant improvement in quality of life. Early treatments have already indicated that DFMO may alleviate symptoms such as developmental delays, low muscle tone, and hair loss. The hope is that as more research is conducted, this drug could become a viable treatment option for those affected, potentially improving muscle strength and overall health outcomes.

Currently, the research is in the early stages, with only a small number of patients treated under an FDA-approved protocol. While initial results are encouraging, progress has been hampered by the disorder’s rarity and the complexities of clinical trials. The FDA has encouraged further study, but logistical challenges remain. The collaboration with Every Cure aims to accelerate research efforts, increase awareness, and ensure that children with BABS are diagnosed and treated appropriately as the science evolves.

As research continues, families affected by rare diseases like BABS should stay informed about new developments and engage with healthcare providers to explore potential treatment options.

Source: sciencedaily.com